The European Commission has approved the use of Novartis’s tisagenlecleucel (Kymriah) and Gilead’s axicabtagene ciloleucel (Yescarta), two chimeric antigen receptor T cell (CAR T) therapies, for certain cancer patients. This new class of therapies has been hailed as a breakthrough in cancer treatment, but cost is a sticking point. Just one day after the European Commission...Continue Reading

When practicing precision oncology for multiple myeloma, clinicians currently match specific DNA mutations to the optimal targeted therapy. However, it may be time to think about incorporating genome-wide RNA profiles to better guide therapy. A new trial published in JCO Precision Oncologyfound that a comprehensive RNA and DNA sequencing platform may benefit late-stage and drug-resistant multiple...Continue Reading